Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Toyoshi Yanagihara; Kunihiro Suzuki; Ayaka Egashira; Naruhiko Ogo; Tatsuma Asoh; Tsukasa Nara; Kensaku Takatsuki; Seiji Yoshizawa; Sy Giin Chong; Naoki Hamada; Takashige Maeyama

doi:10.1016/j.rmcr.2020.101272

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Toyoshi Yanagihara, Kunihiro Suzuki, Ayaka Egashira, Naruhiko Ogo, Tatsuma Asoh, Tsukasa Nara, Kensaku Takatsuki, Seiji Yoshizawa, Sy Giin Chong, Naoki Hamada, Takashige Maeyama

Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

Original language	English
Article number	101272
Journal	Respiratory Medicine Case Reports
Volume	31
DOIs	https://doi.org/10.1016/j.rmcr.2020.101272
Publication status	Published - Jan 2020

All Science Journal Classification (ASJC) codes

Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.rmcr.2020.101272

Cite this

Yanagihara, T., Suzuki, K., Egashira, A., Ogo, N., Asoh, T., Nara, T., Takatsuki, K., Yoshizawa, S., Chong, S. G., Hamada, N., & Maeyama, T. (2020). Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies. Respiratory Medicine Case Reports, 31, Article 101272. https://doi.org/10.1016/j.rmcr.2020.101272

@article{89c8672b67ab4f95a96a0b297025c92c,

title = "Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies",

abstract = "We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.",

author = "Toyoshi Yanagihara and Kunihiro Suzuki and Ayaka Egashira and Naruhiko Ogo and Tatsuma Asoh and Tsukasa Nara and Kensaku Takatsuki and Seiji Yoshizawa and Chong, {Sy Giin} and Naoki Hamada and Takashige Maeyama",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = jan,

doi = "10.1016/j.rmcr.2020.101272",

language = "English",

volume = "31",

journal = "Respiratory Medicine Case Reports",

issn = "2213-0071",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

AU - Yanagihara, Toyoshi

AU - Suzuki, Kunihiro

AU - Egashira, Ayaka

AU - Ogo, Naruhiko

AU - Asoh, Tatsuma

AU - Nara, Tsukasa

AU - Takatsuki, Kensaku

AU - Yoshizawa, Seiji

AU - Chong, Sy Giin

AU - Hamada, Naoki

AU - Maeyama, Takashige

PY - 2020/1

Y1 - 2020/1

N2 - We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

AB - We describe a case of fulminant onset, rapidly progressive-interstitial lung disease (RP-ILD) with anti-ARS antibodies (anti-PL-7). The patient was successfully treated with nintedanib in addition to intensive immunosuppressive therapies, including intravenous cyclophosphamide. Nintedanib has just been approved for treatment of progressive fibrosing ILD, but to date, no reports of RP-ILD treated with nintedanib have been published. This case report may advance discussions regarding the use and timing of nintedanib in treating RP-ILD.

UR - http://www.scopus.com/inward/record.url?scp=85094863681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85094863681&partnerID=8YFLogxK

U2 - 10.1016/j.rmcr.2020.101272

DO - 10.1016/j.rmcr.2020.101272

M3 - Article

AN - SCOPUS:85094863681

SN - 2213-0071

VL - 31

JO - Respiratory Medicine Case Reports

JF - Respiratory Medicine Case Reports

M1 - 101272

ER -

Nintedanib and intensive immunosuppressive therapy to treat rapidly progressive interstitial lung disease presenting anti-ARS antibodies

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this